Notice on the Audit Institution\'s Change of Project Quality Control Reviewers
Announcement on the company\'s president adjustments
Announcement on the company\'s participation in the tenth batch of centralized national drug procurement to win the bid
Notice on the wholly-owned subsidiary Minoxidil Liniment obtaining a drug registration certificate
Explanation by the board of directors of the company on the successive adjustments of incentives and incentive amounts
Notice on Musk Tongxin Dripping Pills being approved as a national protected variety of traditional Chinese medicine to extend the protection period
Announcement on Changing the Legal Representative of the Company and Reissuing the Business License
Announcement Regarding the Election of Employee Representative Directors and Employee Representative Supervisors.
Legal opinion of Beijing Guantao Law Firm (Hangzhou) on Zhejiang Conba Pharmaceutical Co., Ltd.'s second extraordinary general meeting of shareholders in 2024.
Announcement of the resolutions of the second extraordinary shareholders' meeting of the company in 2024.
Announcement Regarding Appointment of Honorary Chairman of the Company
Announcement regarding the election of the board of directors and supervisors, appointment of senior management personnel, and securities affairs representatives.
Board of Directors Compensation and Assessment Committee Rules (Revised August 2024)
Board of directors global strategy and investment decision-making committee working rules (revised in August 2024).
Board of Directors Audit Committee Working Procedures (Revised in August 2024)
Announcement on the increase of specifications supplement approval of acetylcysteine granules by the wholly-owned subsidiary of the company.
Notice regarding the convening of the second extraordinary shareholder meeting in 2024.
Agenda for the Second Extraordinary Shareholder Meeting of Zhejiang Conba Pharmaceutical in 2024.
Announcement regarding pharmaceutical registration certificate obtained by Enthecavir tablets, a fully-owned subsidiary of the company.
Rules of the board of directors' meetings (August 2024)
No Data